Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of ¹⁷⁷ Lu-PSMA-617 in prostate cancer patients.

ABSTRACT: Studies to evaluate and optimize [¹⁷⁷ Lu]Lu-PSMA treatment focus primarily on individual patient data. A population pharmacokinetic (PK) dosimetry model was developed to explore the potential of using imaging data as input for population PK models and to characterize variability in organ and tumor uptake of [¹⁷⁷ Lu]Lu-PSMA-617 in patients with low volume metastatic prostate cancer. Simulations were performed to identify the effect of dose adjustments on absorbed doses in salivary glands and tumors. A six-compartment population PK model was developed, consisting of blood, salivary gland, kidneys, liver, tumor, and a lumped compartment representing other tissue (compartment 1-6, respectively), based on data from 10 patients who received [¹⁷⁷ Lu]Lu-PSMA-617 (2

SUBMITTER: Siebinga H 

PROVIDER: S-EPMC10431047 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature